8W4U image
Entry Detail
PDB ID:
8W4U
EMDB ID:
Title:
human KCNQ2-CaM in complex with PIP2 and HN37
Biological Source:
Source Organism:
Host Organism:
PDB Version:
Deposition Date:
2023-08-25
Release Date:
2023-12-13
Method Details:
Experimental Method:
Resolution:
3.30 Å
Aggregation State:
PARTICLE
Reconstruction Method:
SINGLE PARTICLE
Macromolecular Entities
Polymer Type:polypeptide(L)
Description:Potassium voltage-gated channel subfamily KQT member 2
Chain IDs:A, B, D, F (auth: G)
Chain Length:656
Number of Molecules:4
Biological Source:Homo sapiens
Polymer Type:polypeptide(L)
Description:Calmodulin-1
Chain IDs:C, E (auth: F), G (auth: H), H (auth: E)
Chain Length:149
Number of Molecules:4
Biological Source:Homo sapiens
Primary Citation
Ligand activation mechanisms of human KCNQ2 channel.
Nat Commun 14 6632 6632 (2023)
PMID: 37857637 DOI: 10.1038/s41467-023-42416-x

Abstact

The human voltage-gated potassium channel KCNQ2/KCNQ3 carries the neuronal M-current, which helps to stabilize the membrane potential. KCNQ2 can be activated by analgesics and antiepileptic drugs but their activation mechanisms remain unclear. Here we report cryo-electron microscopy (cryo-EM) structures of human KCNQ2-CaM in complex with three activators, namely the antiepileptic drug cannabidiol (CBD), the lipid phosphatidylinositol 4,5-bisphosphate (PIP2), and HN37 (pynegabine), an antiepileptic drug in the clinical trial, in an either closed or open conformation. The activator-bound structures, along with electrophysiology analyses, reveal the binding modes of two CBD, one PIP2, and two HN37 molecules in each KCNQ2 subunit, and elucidate their activation mechanisms on the KCNQ2 channel. These structures may guide the development of antiepileptic drugs and analgesics that target KCNQ2.

Legend

Protein

Chemical

Disease

Primary Citation of related structures